Biogen Inc. buy UBS Group AG
Start price
24.07.23
/
50%
€249.60
Target price
24.07.24
€302.51
Performance (%)
-16.51%
End price
25.07.24
€208.40
Summary
This prediction ended on 25.07.24 with a price of €208.40. The price of Biogen Inc. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -16.51%. UBS_Group_AG has a follow-up prediction for Biogen Inc. where he still thinks Biogen Inc. is a Buy. UBS_Group_AG has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Biogen Inc. | -1.244% | -1.244% | 58.750% | -27.310% |
| iShares Core DAX® | 0.855% | 0.389% | 2.533% | 52.003% |
| iShares Nasdaq 100 | -0.989% | -4.400% | 25.154% | 77.536% |
| iShares Nikkei 225® | -1.781% | -11.216% | 44.398% | 64.676% |
| iShares S&P 500 | 0.057% | 0.778% | 20.953% | 63.009% |
Comments by UBS_Group_AG for this prediction
In the thread Biogen Inc. diskutieren
Biogen Inc. (NASDAQ: BIIB) had its price target lowered by analysts at UBS Group AG from $346.00 to $335.00. They now have a "buy" rating on the stock.
Ratings data for BIIB provided by MarketBeat
In the thread Trading Biogen Inc.
Die von UBS_Group_AG gewählte maximale Laufzeit wurde überschritten